

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> Life360, Inc.
<b>ARBN:</b> 629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Christopher (Chris) Hulls
<b>Date of last notice</b>	6 June 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect Interests
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Member/shareholder of ICCA Labs, LLC

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Date of change</b>	<ol style="list-style-type: none"> <li>7 June 2024 (PDT) (being 8 June 2024 AEST)</li> <li>17 June 2024 (PDT) (being 18 June 2024 AEST)</li> </ol>
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>2,537,995 CHES Depositary Interests (CDIs)</li> <li>1,276,325 Shares of Common Stock (<b>Shares</b>)(equivalent to 3,828,975 CDIs)</li> <li>2,090,348 Options over Shares (<b>Options</b>)</li> <li>86,554 Restricted Stock Units (<b>RSUs</b>)</li> <li>61,328 Performance Restricted Stock Units (<b>PRSUs</b>)</li> <li>29,960 Shares held by ICCA Labs, LLC<sup>1</sup> )(equivalent to 89,880 CDIs)</li> </ul>
<b>Class</b>	Shares
<b>Number acquired</b>	
<b>Number disposed</b>	<ol style="list-style-type: none"> <li>269,335 Shares (held personally) 19,759 Shares (held by ICCA Labs, LLC)</li> <li>113,890 Shares (held personally) 8,355 Shares (held by ICCA Labs, LLC)</li> </ol>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	US\$27.00 per Share
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>2,537,995 CDIs</li> <li>893,100 Shares (equivalent to 2,679,300 CDIs)</li> <li>2,090,348 Options</li> <li>86,554 RSUs</li> <li>61,328 PRSUs</li> <li>1,846 Shares held by ICCA Labs, LLC (equivalent to 5,538 CDIs)</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Sale of Shares offering in conjunction with an IPO in the USA of Shares in the Company.

## Part 2 – Change of director's interests in contracts

<sup>1</sup> Chris Hulls is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of Shares attributable to Chris Hulls by reason of his membership interest in ICCA Labs, LLC is 29,960.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.